Page last updated: 2024-11-07

3-methoxybenzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID98487
CHEMBL ID123978
SCHEMBL ID283787
MeSH IDM0084201

Synonyms (49)

Synonym
MLS001066418
smr000471856
m-methoxybenzamide
3-methoxybenzamide ,
nsc-28589
m-anisamide
nsc28589
5813-86-5
nsc 28589
benzamide, 3-methoxy-
nsc 209527
einecs 227-379-7
brn 2206857
OPREA1_695428
nsc209527
nsc-209527
3-methoxybenzamide, 97%
3PAX
DB03073
3MB ,
3-methoxy-benzamide
CHEMBL123978 ,
bdbm50106188
cid_98487
BMSE000775
inchi=1/c8h9no2/c1-11-7-4-2-3-6(5-7)8(9)10/h2-5h,1h3,(h2,9,10)
vkplpdimerejjf-uhfffaoysa-
A831753
NCGC00247045-01
3-mba
AKOS005207036
4-10-00-00326 (beilstein handbook reference)
m8502tlk98 ,
unii-m8502tlk98
HMS2267B24
FT-0615984
S5449
SCHEMBL283787
5-methoxybenzamide
3mba
DTXSID00206848
mfcd00007986
NS-01162
F20929
Q27094032
CCG-266212
HY-121497
SB75736
CS-0082205

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Compound 1 displayed suitable in vitro pharmaceutical properties and a favorable in vivo pharmacokinetic profile following intravenous and oral administration, with a calculated bioavailability of 82."( An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy.
Baker, N; Bennett, JM; Berry, J; Collins, I; Czaplewski, LG; Haydon, DJ; Logan, A; Macdonald, R; Macleod, L; Mitchell, JP; Nayal, N; Peasley, H; Srivastava, A; Stokes, NR; Yadav, A, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID743255
Smad3Homo sapiens (human)Potency31.62280.00527.809829.0929AID588855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Poly(adp-ribose) PolymeraseGallus gallus (chicken)IC50 (µMol)10.00000.18003.526710.0000AID977608
Chain A, Poly(adp-ribose) PolymeraseGallus gallus (chicken)IC50 (µMol)10.00000.18003.526710.0000AID977608
Chain A, Poly(adp-ribose) PolymeraseGallus gallus (chicken)IC50 (µMol)10.00000.18003.526710.0000AID977608
Poly [ADP-ribose] polymerase 1Homo sapiens (human)IC50 (µMol)17.00000.00020.81239.8100AID154621
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 beta isoform 1Homo sapiens (human)EC50 (µMol)300.00000.212522.156283.9400AID434954
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrion organizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA metabolic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of protein localizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to oxidative stressPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein modification processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
telomere maintenancePoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
double-strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
apoptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to gamma radiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
carbohydrate biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein autoprocessingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
signal transduction involved in regulation of gene expressionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
macrophage differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of DNA-templated transcription, elongationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to insulin stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to UVPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of circadian sleep/wake cycle, non-REM sleepPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
decidualizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of catalytic activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of mitochondrial depolarizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of SMAD protein signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of necroptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein localization to chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to zinc ionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
replication fork reversalPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of cGAS/STING signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of protein localization to nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of single strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to aldosteronePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of adipose tissue developmentPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to amyloid-betaPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of myofibroblast differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of base-excision repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to nerve growth factor stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ATP generation from poly-ADP-D-ribosePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of ATP biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatin bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
damaged DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
zinc ion bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
enzyme bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein kinase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear estrogen receptor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleosome bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ubiquitin protein ligase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
identical protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein homodimerization activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
histone deacetylase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
R-SMAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD DNA ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator activator activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-tyrosine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-histidine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BS6 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H3S10 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BE35 glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear replication forkPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear envelopePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
membranePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear bodyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-containing complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-DNA complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay IDTitleYearJournalArticle
AID480349Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution assay in presence of 2% bovine serum albumin2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties.
AID759009Inhibition of cell division in penicillin-susceptible Staphylococcus aureus ATCC 25923 at 2048 to 4096 ug/ml after 5 hrs by phase-contrast light microscopy analysis2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ.
AID392210Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 6010552009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID394542Antibacterial activity against Bacillus subtilis bearing FtsZ G196A mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID154621The compound was tested for poly(ADP-ribose)-polymerase (PARP) inhibition2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.
AID394540Antibacterial activity against Staphylococcus aureus bearing FtsZ G266S mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID392214Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 7006982009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID394537Antibacterial activity against Staphylococcus aureus bearing FtsZ G196A mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID759018Antibacterial activity against penicillin-resistant Staphylococcus aureus clinical isolate after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ.
AID392219Antibacterial activity against Staphylococcus epidermidis ATCC 122282009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID394539Antibacterial activity against Staphylococcus aureus bearing FtsZ N263K mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID759021Antibacterial activity against penicillin-susceptible Bacillus subtilis ATCC 9372 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ.
AID394519Antibacterial activity against Staphylococcus aureus by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID392212Antibacterial activity against Staphylococcus aureus ATCC 601055 with FtsZ P300R point mutation2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID759016Antibacterial activity against penicillin-susceptible Streptococcus pyogenes after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ.
AID392206Inhibition of FtsZ-mediated cell division in Bacillus subtilis 168 assessed as drug concentration required to produce filamentation2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID394541Antibacterial activity against Bacillus subtilis bearing FtsZ A47P mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID480351Inhibition of Staphylococcus aureus ATCC 29213 FtsZ assessed as appearance of enlarged cells at 2048 to 4096 ug/mL by light microscopy2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties.
AID394535Antibacterial activity against Staphylococcus aureus bearing FtsZ R191P mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID480348Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties.
AID392208Antibacterial activity against Staphylococcus aureus ATCC 292132009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID759023Inhibition of cell division in penicillin-susceptible Bacillus subtilis ATCC 9372 assessed as lowest concentration required to filamentation after 5 hrs by phase-contrast light microscopy analysis2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ.
AID759020Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ.
AID392211Antibacterial activity against Staphylococcus aureus ATCC 601055 with FtsZ M2181 point mutation2009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID394538Antibacterial activity against Staphylococcus aureus bearing FtsZ V214F mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID392213Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 6070042009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID392218Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 196362009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID759019Antibacterial activity against penicillin-susceptible Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ.
AID392205Antibacterial activity against Bacillus subtilis 1682009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID392216Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 292132009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID392215Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 259232009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID394544Antibacterial activity against Bacillus subtilis bearing FtsZ V307H mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394518Antibacterial activity against Bacillus subtilis by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID392217Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 433002009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID394543Antibacterial activity against Bacillus subtilis bearing FtsZ V307R mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394536Antibacterial activity against Staphylococcus aureus bearing FtsZ G193D mutant by broth microdilution method2008Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896
An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID759017Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ.
AID1811Experimentally measured binding affinity data derived from PDB1998Biochemistry, Mar-17, Volume: 37, Issue:11
Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1998Biochemistry, Mar-17, Volume: 37, Issue:11
Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID493017Wombat Data for BeliefDocking2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (46.67)18.7374
1990's25 (33.33)18.2507
2000's5 (6.67)29.6817
2010's8 (10.67)24.3611
2020's2 (2.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.26 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.32%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other75 (98.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]